

ITJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application : Anthony H. Cincotta
Serial No. : 10/627,014
Filed : July 25, 2003
For : THERAPEUTIC TREATMENT FOR THE
METABOLIC SYNDROME AND TYPE 2
DIABETES

Examiner :
Attorney Docket : 102392-200
Group Art Unit : 1617
Confirmation No. : 3686
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 16 Nov 2007.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE LETTER

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.

The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

1. International Application No. WO 97/41873 (CINCOTTA, ANTHONY H.) 13 November 1997 (1997-11-13).
2. CINCOTTA, ANTHONY H., ET AL., "*Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes*", EXPERT OPINION ON INVESTIGATIONAL DRUGS, Ashley Publications Ltd., United Kingdom, Vol. 8, No. 10, Pages 1683-1707 (1999); XP002453155.
3. PIJL, H and MEINDER, E.A., "*Modulation of monoaminergic neural circuits: Potential for the treatment of type 2 diabetes mellitus*", DATABASE EMBASE [Online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, Treatments in Endocrinology, Vol. 1, No. 2, Pages 71-78 (2002); XP002453157.

Applicant submits that copies of the above-cited references are enclosed herewith.

If the Examiner has any questions or feels that a discussion with Applicant's representative would expedite prosecution, the Examiner is invited and encouraged to contact Applicant's undersigned representative at the telephone number listed below.

Respectfully submitted,

ANTHONY H. CINCOTTA

Date: 16 Nov 2007

By: Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832
Telephone: (203) 498-4400
Facsimile: (203) 782-2889



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application : Anthony H. Cincotta
Serial No. : 10/627,014
Filed : July 25, 2003
For : THERAPEUTIC TREATMENT FOR THE
METABOLIC SYNDROME AND TYPE 2
DIABETES

Examiner :
Attorney Docket : 102392-200
Group Art Unit : 1617
Confirmation No. : 3686
Customer No. : 27267

I hereby certify that this correspondence is being deposited with the United States Postal Service, First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 16 Nov 2007.

By Todd E. Garabedian
Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MAIL STOP AMENDMENT
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §1.56, the Examiner is respectfully requested to consider the references cited on attached Form PTO-1449. A copy of each reference (if not previously submitted) is enclosed. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- [] 1. This Information Disclosure Statement is being filed within three months of the U. S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

- ☒ 2. This Information Disclosure Statement is being filed more than three months after the U. S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- ☒ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2); and no fee is required under 37 C.F.R. §1.17(p).
- ☐ Please charge Deposit Account No. 23-1665 in the amount of \$180.00 in payment of the fee under 37 C.F.R. §1.17(p). Two additional copies of this Information Disclosure Statement are enclosed.
- ☐ A check in the amount of \$180.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(p).
- ☐ 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered.
- ☐ a. Each item of information contained on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(1).

- [] b. No item of information cited on Form PTO-1449 filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. §1.97(e)(2).
- [] Please charge Deposit Account No. 23-1665 in the amount of \$130.00 in payment of the fee under 37 C.F.R. §1.17(i)(1). Two additional copies of this Information Disclosure Statement are enclosed.
- [] A check in the amount of \$130.00 is attached hereto in payment of the fee under 37 C.F.R. §1.17(i)(1).

The undersigned represents that the closest art of which he is presently aware has been cited herein and understands that this statement shall not be construed as a representation that no better art exists or that a thorough patentability search has been made.


The undersigned further represents that the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

Respectfully submitted,

ANTHONY H. CINCOTTA

Date: 16 Nov 2007

By:



Todd E. Garabedian, Ph.D.
Registration No. 39,197
Attorney for Applicant

WIGGIN AND DANA LLP
One Century Tower
P. O. Box 1832
New Haven, CT 06508-1832

Telephone : (203) 498-4400
Telecopier: (203) 782-2889